TY  - CONF
AU  - Dinić, Miroslav
AU  - Bisenić, Aleksandar
AU  - Jakovljević, Stefan
AU  - Nastasijević, Branislav
AU  - Brdarić, Emilija
AU  - Soković Bajić, Svetlana
AU  - Đokić, Jelena
AU  - Terzić-Vidojević, Amarela
AU  - Golić, Nataša
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2129
AB  - Introduction: Gut-brain axis has been identified as an important target for prevention of neurodegenerative and psychiatric disease. To date, specific microbial strains resident in the intestinal ecosystem
have been described to modulate several behaviour-related functions in the host. Faecalimonas sp. is
anaerobic bacteria affiliated with the family Lachnospiraceae, which represents a highly prevalent beneficial bacteria in the human gut and have potential to be used as next generation probiotic.
Methods: Faecalimonas sp. NGB245 was isolated from human fecal material by pre-inoculation in
BACTEC media followed by serial dilutions spreading on Columbia Blood Agar supplemented with cysteine and sodium thioglycolate in Whitley Anaerobic Workstation. Production of short chain fatty acid
(SCFA) was detected after bacterial growth in Columbia broth supplemented with cellobiose by HPLC.
Host response was followed on Caenorhabditis elegans model by evaluated expression of the genes involved in neurosignaling by qPCR.
Results: We showed that Faecalimonassp. NGB245 exhibits high capacity of production of SCFA including acetate (12,17 mM), propionate (3,02 mM) and butyrate (10,33 mM). Moreover, C. elegansfed with Faecalimonas sp. NGB245 showed higher expression of the genes involved in neurotransmitter synthesis
(tph-1, cat-2), neurotransmitter release (unc-64, snb-1, snt-1), neurotransmitter receptor (npr-1) and different classes of neuropeptides(flp-18, flp-21, nlp-28, nlp-29) in comparison to wormsfed with Escherichia
coli OP50, as a standard laboratory food.
Conclusion: The obtained results imply that Faecalimonas sp. NGB245 isolate could be considered as
next generation probiotic to be used in prevention and treatment of neurodegenerative and psychiatric
diseases.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Short chain fatty acid producing faecalimonas sp. NGB245 isolated from human gut modulates neurosignaling in Caenorhabditis elegans
EP  - 124
SP  - 124
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2129
ER  - 

@conference{
author = "Dinić, Miroslav and Bisenić, Aleksandar and Jakovljević, Stefan and Nastasijević, Branislav and Brdarić, Emilija and Soković Bajić, Svetlana and Đokić, Jelena and Terzić-Vidojević, Amarela and Golić, Nataša",
year = "2023",
abstract = "Introduction: Gut-brain axis has been identified as an important target for prevention of neurodegenerative and psychiatric disease. To date, specific microbial strains resident in the intestinal ecosystem
have been described to modulate several behaviour-related functions in the host. Faecalimonas sp. is
anaerobic bacteria affiliated with the family Lachnospiraceae, which represents a highly prevalent beneficial bacteria in the human gut and have potential to be used as next generation probiotic.
Methods: Faecalimonas sp. NGB245 was isolated from human fecal material by pre-inoculation in
BACTEC media followed by serial dilutions spreading on Columbia Blood Agar supplemented with cysteine and sodium thioglycolate in Whitley Anaerobic Workstation. Production of short chain fatty acid
(SCFA) was detected after bacterial growth in Columbia broth supplemented with cellobiose by HPLC.
Host response was followed on Caenorhabditis elegans model by evaluated expression of the genes involved in neurosignaling by qPCR.
Results: We showed that Faecalimonassp. NGB245 exhibits high capacity of production of SCFA including acetate (12,17 mM), propionate (3,02 mM) and butyrate (10,33 mM). Moreover, C. elegansfed with Faecalimonas sp. NGB245 showed higher expression of the genes involved in neurotransmitter synthesis
(tph-1, cat-2), neurotransmitter release (unc-64, snb-1, snt-1), neurotransmitter receptor (npr-1) and different classes of neuropeptides(flp-18, flp-21, nlp-28, nlp-29) in comparison to wormsfed with Escherichia
coli OP50, as a standard laboratory food.
Conclusion: The obtained results imply that Faecalimonas sp. NGB245 isolate could be considered as
next generation probiotic to be used in prevention and treatment of neurodegenerative and psychiatric
diseases.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Short chain fatty acid producing faecalimonas sp. NGB245 isolated from human gut modulates neurosignaling in Caenorhabditis elegans",
pages = "124-124",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2129"
}

Dinić, M., Bisenić, A., Jakovljević, S., Nastasijević, B., Brdarić, E., Soković Bajić, S., Đokić, J., Terzić-Vidojević, A.,& Golić, N.. (2023). Short chain fatty acid producing faecalimonas sp. NGB245 isolated from human gut modulates neurosignaling in Caenorhabditis elegans. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 124-124.
https://hdl.handle.net/21.15107/rcub_imagine_2129

Dinić M, Bisenić A, Jakovljević S, Nastasijević B, Brdarić E, Soković Bajić S, Đokić J, Terzić-Vidojević A, Golić N. Short chain fatty acid producing faecalimonas sp. NGB245 isolated from human gut modulates neurosignaling in Caenorhabditis elegans. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:124-124.
https://hdl.handle.net/21.15107/rcub_imagine_2129 .

Dinić, Miroslav, Bisenić, Aleksandar, Jakovljević, Stefan, Nastasijević, Branislav, Brdarić, Emilija, Soković Bajić, Svetlana, Đokić, Jelena, Terzić-Vidojević, Amarela, Golić, Nataša, "Short chain fatty acid producing faecalimonas sp. NGB245 isolated from human gut modulates neurosignaling in Caenorhabditis elegans" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):124-124,
https://hdl.handle.net/21.15107/rcub_imagine_2129 .

TY  - JOUR
AU  - Mitrović, Miloš
AU  - Stanković-Popović, Verica
AU  - Tolinački, Maja
AU  - Golić, Nataša
AU  - Soković Bajić, Svetlana
AU  - Veljović, Katarina
AU  - Nastasijević, Branislav
AU  - Soldatović, Ivan
AU  - Svorcan, Petar
AU  - Dimković, Nada
PY  - 2023
UR  - https://www.sciencedirect.com/science/article/pii/S1051227622001522
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1753
AB  - ObjectiveAltering dysbiotic gut flora through synbiotic supplementation has recently been recognized as a potential treatment strategy to reduce the levels of gut-derived uremic toxins and decrease inflammation. Assessing its efficacy and safety has been the main goal of our randomized, double-blind, placebo-controlled study.MethodsA total of 34 nondialyzed chronic kidney disease patients, aged ≥18 years, with an estimated glomerular filtration rate between 15 and 45 mL/minute, were randomized either to an intervention group (n = 17), receiving synbiotic (Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, 32 billion colony forming units per day plus 3.2 g of inulin), or control group (n = 17), receiving placebo during 12 weeks. The impact of treatment on the dynamic of serum levels of gut-derived uremic toxins, total serum indoxyl sulfate, p-cresyl sulfate, and trimethylamine N-oxide, was defined as the primary outcome of the study. Secondary outcomes included changes in the stool microbiome, serum interleukin-6 levels, high-sensitivity C-reactive protein, estimated glomerular filtration rate, albuminuria, diet, gastrointestinal symptom dynamics, and safety. Serum levels of uremic toxins were determined using ultraperformance liquid chromatography. The stool microbiome analysis was performed using the 16S ribosomal ribonucleic acid gene sequencing approach.ResultsSynbiotic treatment significantly modified gut microbiome with Bifidobacteria, Lactobacillus, and Subdoligranulum genera enrichment and consequently reduced serum level of indoxyl sulfate (ΔIS –21.5% vs. 5.3%, P < .001), improved estimated glomerular filtration rate (ΔeGFR 12% vs. 8%, P = .029), and decreased level of high-sensitivity C-reactive protein (–39.5 vs. –8.5%, P < .001) in treated patients. Two patients of the intervention arm complained of increased flatulence. No other safety issues were noted.ConclusionSynbiotics could be available, safe, and an effective therapeutic strategy we could use in daily practice in order to decrease levels of uremic toxins and microinflammation in chronic kidney disease patients.
T2  - Journal of Renal Nutrition
T2  - Journal of Renal NutritionJournal of Renal Nutrition
T1  - The impact of synbiotic treatment on the levels of gut-derived uremic zoxins, inflammation, and gut microbiome of chronic kidney disease patients - a randomized trial
EP  - 288
IS  - 2
SP  - 278
VL  - 33
DO  - 10.1053/j.jrn.2022.07.008
ER  - 

@article{
author = "Mitrović, Miloš and Stanković-Popović, Verica and Tolinački, Maja and Golić, Nataša and Soković Bajić, Svetlana and Veljović, Katarina and Nastasijević, Branislav and Soldatović, Ivan and Svorcan, Petar and Dimković, Nada",
year = "2023",
abstract = "ObjectiveAltering dysbiotic gut flora through synbiotic supplementation has recently been recognized as a potential treatment strategy to reduce the levels of gut-derived uremic toxins and decrease inflammation. Assessing its efficacy and safety has been the main goal of our randomized, double-blind, placebo-controlled study.MethodsA total of 34 nondialyzed chronic kidney disease patients, aged ≥18 years, with an estimated glomerular filtration rate between 15 and 45 mL/minute, were randomized either to an intervention group (n = 17), receiving synbiotic (Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, 32 billion colony forming units per day plus 3.2 g of inulin), or control group (n = 17), receiving placebo during 12 weeks. The impact of treatment on the dynamic of serum levels of gut-derived uremic toxins, total serum indoxyl sulfate, p-cresyl sulfate, and trimethylamine N-oxide, was defined as the primary outcome of the study. Secondary outcomes included changes in the stool microbiome, serum interleukin-6 levels, high-sensitivity C-reactive protein, estimated glomerular filtration rate, albuminuria, diet, gastrointestinal symptom dynamics, and safety. Serum levels of uremic toxins were determined using ultraperformance liquid chromatography. The stool microbiome analysis was performed using the 16S ribosomal ribonucleic acid gene sequencing approach.ResultsSynbiotic treatment significantly modified gut microbiome with Bifidobacteria, Lactobacillus, and Subdoligranulum genera enrichment and consequently reduced serum level of indoxyl sulfate (ΔIS –21.5% vs. 5.3%, P < .001), improved estimated glomerular filtration rate (ΔeGFR 12% vs. 8%, P = .029), and decreased level of high-sensitivity C-reactive protein (–39.5 vs. –8.5%, P < .001) in treated patients. Two patients of the intervention arm complained of increased flatulence. No other safety issues were noted.ConclusionSynbiotics could be available, safe, and an effective therapeutic strategy we could use in daily practice in order to decrease levels of uremic toxins and microinflammation in chronic kidney disease patients.",
journal = "Journal of Renal Nutrition, Journal of Renal NutritionJournal of Renal Nutrition",
title = "The impact of synbiotic treatment on the levels of gut-derived uremic zoxins, inflammation, and gut microbiome of chronic kidney disease patients - a randomized trial",
pages = "288-278",
number = "2",
volume = "33",
doi = "10.1053/j.jrn.2022.07.008"
}

Mitrović, M., Stanković-Popović, V., Tolinački, M., Golić, N., Soković Bajić, S., Veljović, K., Nastasijević, B., Soldatović, I., Svorcan, P.,& Dimković, N.. (2023). The impact of synbiotic treatment on the levels of gut-derived uremic zoxins, inflammation, and gut microbiome of chronic kidney disease patients - a randomized trial. in Journal of Renal Nutrition, 33(2), 278-288.
https://doi.org/10.1053/j.jrn.2022.07.008

Mitrović M, Stanković-Popović V, Tolinački M, Golić N, Soković Bajić S, Veljović K, Nastasijević B, Soldatović I, Svorcan P, Dimković N. The impact of synbiotic treatment on the levels of gut-derived uremic zoxins, inflammation, and gut microbiome of chronic kidney disease patients - a randomized trial. in Journal of Renal Nutrition. 2023;33(2):278-288.
doi:10.1053/j.jrn.2022.07.008 .

Mitrović, Miloš, Stanković-Popović, Verica, Tolinački, Maja, Golić, Nataša, Soković Bajić, Svetlana, Veljović, Katarina, Nastasijević, Branislav, Soldatović, Ivan, Svorcan, Petar, Dimković, Nada, "The impact of synbiotic treatment on the levels of gut-derived uremic zoxins, inflammation, and gut microbiome of chronic kidney disease patients - a randomized trial" in Journal of Renal Nutrition, 33, no. 2 (2023):278-288,
https://doi.org/10.1053/j.jrn.2022.07.008 . .